Skip to main content
Weight LossDual GIP + GLP-1 receptor agonist

Tirzepatide

Also known as: Mounjaro, Zepbound, LY3298176

By the Peptide Dossier Editorial TeamUpdated How we source

Tirzepatide is a weekly dual GIP/GLP-1 receptor agonist. Mounjaro and Zepbound share the active ingredient but have separate indication, age-group and product-label contexts; evidence depends on the population and endpoint.

Quick Facts

Class:Dual GIP + GLP-1 receptor agonist
US product context:FDA-approved Mounjaro and Zepbound products have distinct diabetes, cardiovascular, weight and sleep-apnea contexts; compounded tirzepatide is not approved.
Evidence context:Large randomized programs support indication-specific glucose, weight and sleep-apnea outcomes; estimand, population and comparator matter.

Identity and mechanism

Eli Lilly’s tirzepatide is a synthetic 39-amino-acid peptide acting at GIP and GLP-1 receptors. Those gut-hormone pathways increase glucose-dependent insulin secretion, reduce glucagon, slow gastric emptying and decrease appetite and food intake. It is given by weekly subcutaneous injection.

Mounjaro and Zepbound contain the same active ingredient but carry different labeling. Compared with GLP-1-only medicines such as semaglutide, the distinguishing pharmacology is the additional GIP receptor activity. Reported lipid effects include lower LDL cholesterol and triglycerides; mechanism and observed clinical outcomes remain separate evidence categories.

Sources: [1], [5], [9], [12]

Approval history and prescribed populations

Tirzepatide product-specific approval history
DateProductApproved context in the published account
2022MounjaroType 2 diabetes; original approval in May.
2023ZepboundChronic weight management; approval in November.
December 2024ZepboundModerate-to-severe obstructive sleep apnea in adults with obesity.
December 2025MounjaroPediatric type 2 diabetes from age 10.
August 2026MounjaroMajor cardiovascular-event risk reduction in high-risk adults with type 2 diabetes.

Mounjaro accompanies diet and exercise for glucose control in adults and children aged ten and above with type 2 diabetes. Its cardiovascular-risk use concerns high-risk adults with type 2 diabetes. Zepbound weight-management eligibility concerns adults with BMI at least 30, or at least 27 plus a weight-related condition such as hypertension or high cholesterol. Its sleep-apnea indication concerns adults with obesity.

Compounded tirzepatide is not FDA-approved or FDA-evaluated for safety, effectiveness or quality. The branded indications do not confer approval on compounded products.

Sources: [3], [4], [10], [11], [13]

Weight-loss and maintenance studies

Tirzepatide weight and withdrawal evidence
TrialPopulation and durationResults
SURMOUNT-12,539 adults with obesity or overweight plus a complication, without diabetes; 72 weeksTreatment-regimen mean weight changes: −15.0%, −19.5% and −20.9% for 5, 10 and 15 mg; −3.1% placebo. The estimand includes treatment discontinuation.
SURMOUNT-2938 adults with type 2 diabetes and obesity; 72 weeksWeight reductions: 12.8% at 10 mg and 14.7% at 15 mg versus 3.2% placebo; differences 9.6 and 11.6 percentage points.
SURMOUNT-436-week open-label run-in followed by randomized withdrawal in 670 peopleAfter 20.9% mean run-in loss, continued treatment produced a further 5.5% loss; placebo switch produced 14.0% regain. Difference 19.4 percentage points; total from initial baseline −25.3% versus −9.9%.

Different diabetes status, durations and analysis methods affect interpretation. Individual results varied. The SURMOUNT-1 figures above use the treatment-regimen estimand, which includes treatment discontinuation; estimates based on a different analysis may differ.

Sources: [2], [7], [8]

Sleep apnea and diabetes-progression findings

The two SURMOUNT-OSA studies together enrolled 469 adults with obesity and moderate-to-severe obstructive sleep apnea. In the 52-week study without PAP use, maximum-tolerated tirzepatide lowered apnea-hypopnea index by 25.3 events/hour. The between-group difference was 20.0 events/hour (95% CI 14.2–25.8), with benefit linked to weight loss. The program supported the December 2024 approval.

A 176-week SURMOUNT-1 analysis of 1,032 participants with obesity and prediabetes found progression to type 2 diabetes in 1.3% on tirzepatide versus 13.3% on placebo (hazard ratio 0.07; reported 95% CI 0.0–0.1). Mean weight reductions were 12.3%, 18.7% and 19.7% at 5, 10 and 15 mg, respectively, versus 1.3% with placebo. This research population should be stated when discussing diabetes prevention.

Sources: [14], [15]

Comparative evidence with semaglutide

A 2025 synthesis of seven direct comparative studies included 28,980 participants: five observational studies and two randomized trials. It associated tirzepatide with greater weight reduction and higher odds of reaching at least 10% loss, but between-study heterogeneity was high. The reported standardized mean difference for weight loss was 0.75 (95% CI 0.52–0.92); that statistic is not an odds ratio.

A separate 2024 network meta-analysis of 28 randomized trials involving 23,622 adults with type 2 diabetes estimated placebo-adjusted HbA1c reductions of 1.96 percentage points with tirzepatide 15 mg and 1.59 with semaglutide 2.0 mg, rated comparable in that analysis. Estimated weight changes were −9.57 kg and −4.97 kg, respectively. Network comparisons are not equivalent to a single matched head-to-head trial. Both treatments can cause gastrointestinal events, especially at higher tirzepatide doses.

Separate placebo-controlled trials should not be used alone to declare a direct comparative advantage. Our existing tirzepatide–semaglutide comparison provides additional context.

Sources: [6], [16]

Dosing and product instructions

The existing Zepbound label starts at 2.5 mg weekly for four weeks. Increases are in 2.5 mg steps after at least four weeks at the current dose, depending on response and tolerability. Maintenance doses differ by indication; reaching 15 mg on a fixed calendar is not required. Available strengths are 2.5, 5, 7.5, 10, 12.5 and 15 mg, and the approximate half-life is five days.

Numbers embedded in study summaries are trial doses, not a substitute for the prescribed product’s instructions.

Sources: [17]

Adverse effects and contraindications

Common effects include nausea, diarrhea, vomiting, constipation, abdominal pain, reduced appetite, indigestion, fatigue, injection-site reactions, allergic reactions, belching, hair loss and heartburn. Gastrointestinal symptoms are often more prominent during dose escalation.

The boxed thyroid C-cell-tumor warning comes from rodent findings; whether that risk occurs in humans is unknown. Personal or family medullary thyroid carcinoma, MEN 2 and known tirzepatide hypersensitivity are contraindications. Other important risks include pancreatitis, gallbladder disease/stones, dehydration-related acute kidney injury, worsening diabetic retinopathy, and hypoglycemia particularly with insulin or sulfonylureas. Delayed gastric emptying can contribute to aspiration risk during anesthesia or surgery.

The product label advises people using oral hormonal contraception to use a non-oral method or add a barrier method for four weeks after initiation and after each dose increase. These points do not replace the full label or individualized prescribing decisions.

References and further reading

This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .

  1. accessdata.fda.govIdentity and mechanismCited in: Identity and mechanism
  2. 10.1056/NEJMoa2206038Weight-loss and maintenance studiesCited in: Weight-loss and maintenance studies
  3. accessdata.fda.govApproval history and prescribed populationsCited in: Approval history and prescribed populations
  4. fda.govApproval history and prescribed populationsCited in: Approval history and prescribed populations
  5. 10.3390/ijms232314631Identity and mechanismCited in: Identity and mechanism
  6. 10.1007/s00125-024-06144-1Comparative evidence with semaglutideCited in: Comparative evidence with semaglutide
  7. 10.1001/jama.2023.24945Weight-loss and maintenance studiesCited in: Weight-loss and maintenance studies
  8. 10.1016/S0140-6736(23)01200-XWeight-loss and maintenance studiesCited in: Weight-loss and maintenance studies
  9. accessdata.fda.govIdentity and mechanismCited in: Identity and mechanism
  10. accessdata.fda.govApproval history and prescribed populationsCited in: Approval history and prescribed populations
  11. accessdata.fda.govApproval history and prescribed populationsCited in: Approval history and prescribed populations
  12. accessdata.fda.govIdentity and mechanismCited in: Identity and mechanism
  13. fda.govApproval history and prescribed populationsCited in: Approval history and prescribed populations
  14. 10.1056/NEJMoa2404881Sleep apnea and diabetes-progression findingsCited in: Sleep apnea and diabetes-progression findings
  15. 10.1056/NEJMoa2410819Sleep apnea and diabetes-progression findingsCited in: Sleep apnea and diabetes-progression findings
  16. 10.7759/cureus.86080Comparative evidence with semaglutideCited in: Comparative evidence with semaglutide
  17. pi.lilly.com — additional readingDosing and product instructionsCited in: Dosing and product instructions
  18. pubmed.ncbi.nlm.nih.gov — additional reading

Frequently Asked Questions About Tirzepatide

At 72 weeks, the treatment-regimen estimand showed 20.9% mean weight reduction for 15 mg versus 3.1% with placebo. Different published estimands describe different treatment-effect questions.

No. Zepbound dose selection depends on response, tolerability and indication. Its label sets minimum intervals between increases rather than requiring automatic monthly escalation.

They contain tirzepatide, but have distinct labeling and approved-use contexts. Use the prescribed product’s instructions.

It stimulates both GIP and GLP-1 receptors, influencing insulin, glucagon, gastric emptying and appetite. Semaglutide activates GLP-1 alone. Clinical comparisons still require matched evidence rather than a mechanistic assumption.

In 2,539 adults without diabetes, 72-week treatment-regimen weight reduction ranged from 15.0% to 20.9% versus 3.1% placebo. In SURMOUNT-4, after 20.9% run-in loss, continuing treatment produced further loss while switching to placebo led to 14.0% regain, supporting continued-treatment maintenance rather than a permanent off-treatment effect.

SURMOUNT-2 enrolled 938 people for 72 weeks. Weight reductions were 12.8% at 10 mg and 14.7% at 15 mg, versus 3.2% placebo. These were smaller than in SURMOUNT-1, which excluded diabetes.

Approved-use information lists Mounjaro for type 2 diabetes from age ten and cardiovascular risk reduction in high-risk adults with type 2 diabetes, and Zepbound for adult weight management and moderate-to-severe sleep apnea with obesity. Compounded tirzepatide has no FDA approval.

Across two SURMOUNT-OSA trials there were 469 participants. In the study without PAP therapy, 52-week apnea-hypopnea index fell 25.3 events/hour on tirzepatide; the treatment difference versus placebo was 20.0 events/hour (95% CI 14.2–25.8).

Yes. Over 176 weeks in 1,032 participants with obesity and prediabetes, diabetes developed in 1.3% on tirzepatide versus 13.3% placebo. Published reports describe HR 0.07 with 95% CI 0.0–0.1. This does not remove the need to identify the study population.

A mixed-design direct-comparison synthesis favored tirzepatide but had substantial heterogeneity. A separate network analysis estimated larger weight reduction with tirzepatide 15 mg than semaglutide 2.0 mg in type 2 diabetes. These designs and doses should not be conflated with a single head-to-head trial.

No. The label specifies minimum intervals between increases and considers indication, response and tolerability rather than mandatory automatic monthly escalation.

They share tirzepatide but have distinct labeling and approved-use contexts. Follow the product actually prescribed.

Related Peptides

Continue exploring Tirzepatide

Search all related references →

Our library review is ongoing. Read how we evaluate evidence or report a correction.

Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.